ArticleBlood cells, molecules & diseases2020
Increased expression of CD8 marker on T-cells in COVID-19 patients.
Article in Blood cells, molecules & diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04531319 (Evaluation of Immune Cell Subgroups in Covid 19 Patients), which is not on this map. Cited by 90 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Immune Cell Subgroups in Covid 19 Patients
Who cites it
90 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review.Journal of medical virology · 2021Pooled it
- Add-on effect of Chinese herbal medicine in the treatment of mild to moderate COVID-19: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Pooled it
- Valganciclovir modulates the tumor necrosis factor axis molecules expression and CD4+ T-cell subsets in disseminated Kaposi Sarcoma patients.Clinical and experimental immunology · 2024Trial
- Increased B-cell activity with consumption of activated monocytes in severe COVID-19 patients.European journal of immunology · 2021Trial
- Surrogate virus neutralization test to determine salivary neutralizing antibody inhibition of ACE2 and SARS-CoV-2 spike RBD complex.Frontiers in immunology · 2026Article
- Frequencies of PD-1 and LAG-3 positive T cells in asthmatic children and their relationship with inflammatory cytokines.Open medicine (Warsaw, Poland) · 2026Article
- Review
- Medication, Nutrition, and Hygiene in COVID-19 Prevention and Treatment: A Comprehensive Narrative Review.Global challenges (Hoboken, NJ) · 2025Review
- Methylation patterns of the nasal epigenome of hospitalized SARS-CoV-2 positive patients reveal insights into molecular mechanisms of COVID-19.BMC medical genomics · 2025Article
- Analysis of humoral and cellular immune activation up to 21 months after heterologous and homologous COVID-19 vaccination.Frontiers in immunology · 2025Article
- Study of Peripheral Blood T-Lymphocytes and Their Subpopulations in COVID-19 Patients.Biochemistry research international · 2025Article
- Decrease in CD4 and CD8 lymphocytes are predictors of severe clinical picture and unfavorable outcome of the disease in patients with COVID-19.Open medicine (Warsaw, Poland) · 2025Article
- Clinical Characteristics and Prognostic Factors of Severe COVID-19.Infection and drug resistance · 2025Article
- Association of COVID-19 with thyroid dysfunction and autoimmune thyroid disease: A retrospective cohort study.Journal of translational autoimmunity · 2024Article
- Pathophysiological, immunological, and inflammatory features of long COVID.Frontiers in immunology · 2024Review
- Effects of metformin therapy on HMGB1 levels in rheumatoid arthritis patients.European journal of medical research · 2023Article
- Pathological Effects of SARS-CoV-2 Associated with Hematological Abnormalities.Current issues in molecular biology · 2023Review
- Article
- Ketogenic Diet and Ketone Bodies as Clinical Support for the Treatment of SARS-CoV-2-Review of the Evidence.Viruses · 2023Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCell-mediated immunity including T-cells (T helper and cytotoxic) plays an essential role in efficient antiviral responses against coronavirus disease-2019 (COVID-19). Therefore, in this study, we evaluated the ratio and expression of CD4 and CD8 markers in COVID-19 patients to clarify the immune characterizations of CD4 and CD8 T-cells in COVID-19 patients.
methodsPeripheral blood samples of 25 COVID-19 patients and 25 normal individuals with similar age and sex as the control group were collected. White blood cells, platelets, and lymphocytes were counted and CD4 and CD8 T lymphocytes were evaluated by flow cytometry.
resultsThe number of white blood cells, lymphocytes, and platelets were reduced significantly in COVID-19 patients (P < 0.05). The difference in CD4:CD8 ratio, CD4 T-cell frequency, CD8 T-cell frequency, and CD4 mean fluorescence intensity (MFI) was not significant between COVID-19 patients and healthy individuals (P > 0.05); however, the CD8 MFI increased significantly in COVID-19 infected patients (P < 0.05).
conclusionAlthough, there is no significant difference in the ratio of CD4 to CD8 between two groups, the expression level of CD8 in COVID-19 patients was significantly higher than the normal individuals. This result suggested that the cellular immune responses triggered by COVID-19 infection were developed through overexpression of CD8 and hyperactivation of cytotoxic T lymphocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.